BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer
- Others:
- Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- Human Biobank CHUN ; Hôpital Pasteur [Nice] (CHU)
- Laboratoire de Pathologie Clinique et Expérimentale. Hôpital Pasteur [Nice] ; Hôpital Pasteur [Nice] (CHU)
- L'Association pour la Recherche contre le Cancer (ARC)
- Service de Chirurgie thoracique ; Centre Hospitalier Universitaire de Nice (CHU Nice)
- Service de Pathologie [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
- Département de pathologie [Hôpital Haut Lévêque] ; Hôpital Haut-Lévêque [CHU Bordeaux] ; CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux]
- Service de pathologie [CHU Ambroise Paré] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP]
- Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay
- Service de gastroentérologie ; Hôpital l'Archet
Description
The BRAFV600E mutation confers worse prognosis to metastatic colorectal cancer (mCRC) patients. In addition, this mutation has a negative predictive value for response to treatment with monoclonal antibodies against EGFR in patients with KRAS wild-type (wt) mCRC. The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAFV600E in the thoracic metastases of sporadic mCRC patients has not been evaluated until now. The purpose of this study was to compare BRAFV600E IHC staining with molecular biologymethodsandto definethe diagnostic value of the VE1 antibody for the detection of BRAFV600E in this population. BRAF mutations were analysed by two DNA sequencing methods (pyrosequencing and Sanger sequencing) in a Caucasian population of 310 sporadic mCRC with thoracic metastases patients expressing KRAS wt. Detection of the BRAFV600E mutation was performed in the corresponding tumours by IHC using the VE1 antibody and compared to results of the DNA-based assays. Thirty-nine out of 310 (13%) of tumours harboured a BRAF mutation, which corresponded to either a BRAFV600E in 34 of 310 (11%) cases or a non-BRAFV600E mutation in 5 of 310 (2%) cases. IHC with VE1 was strongly positive in 32 of 34 (88%) BRAFV600E mutated tumours and negative in non-BRAFV600E mutated tumours. IHC using the VE1 clone is a specific and sensitive method for the detection of BRAFV600E and may be either a complementary or an alternative method to molecular testing in mCRC patients.
Abstract
International audience
Additional details
- URL
- https://hal.univ-lorraine.fr/hal-01687376
- URN
- urn:oai:HAL:hal-01687376v1
- Origin repository
- UNICA